Novel oral transforming growth factor-beta signaling inhibitor EW-7197 eradicates CML-initiating cells by Naka, Kazuhito et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2016-02-01 
Novel oral transforming growth factor-beta signaling inhibitor 
EW-7197 eradicates CML-initiating cells 
Kazuhito Naka 
Kanazawa University 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cancer Biology Commons, Hematology Commons, Hemic and Lymphatic Diseases 
Commons, Neoplasms Commons, and the Oncology Commons 
Repository Citation 
Naka K, Li S, Kim D. (2016). Novel oral transforming growth factor-beta signaling inhibitor EW-7197 
eradicates CML-initiating cells. Open Access Articles. https://doi.org/10.1111/cas.12849. Retrieved from 
https://escholarship.umassmed.edu/oapubs/2755 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Novel oral transforming growth factor-b signaling
inhibitor EW-7197 eradicates CML-initiating cells
Kazuhito Naka,1,2 Kaori Ishihara,1 Yoshie Jomen,1 Cheng Hua Jin,3 Dong-Hyun Kim,4 Yoon-Kang Gu,4 Eun-Sook
Jeong,4 Shaoguang Li,5 Daniela S. Krause,6 Dong-Wook Kim,7 Eunjin Bae,1,8 Yoshihiro Takihara,2 Atsushi Hirao,9
Hiroko Oshima,10 Masanobu Oshima,10 Akira Ooshima,8 Yhun Yhong Sheen,11 Seong-Jin Kim8 and Dae-Kee Kim3
1Exploratory Project on Cancer Stem Cells, Cancer Research Institute, Kanazawa University, Kanazawa; 2Department of Stem Cell Biology, Research Institute
for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; 3Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha
Womans University, Seoul; 4Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Korea;
5Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA; 6Institute for
Tumor Biology and Experimental Therapy, Georg Speyer Haus, Goethe University, Frankfurt, Germany; 7Department of Hematology, Seoul St. Mary’s
Hospital, Cancer Research Institute, The Catholic University of Korea, Seoul; 8CHA Cancer Institute and Department of Biomedical Science, CHA University,
Seongnam, Korea; 9 Divisions of Molecular Genetics; 10 Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; 11College of Pharmacy,
Ewha Womans University, Seoul, Korea
Key words
ALK5 inhibitor, CML stem cells, relapse prevention, TGF-b
signaling, TKI resistance
Correspondence
Kazuhito Naka, Department of Stem Cell Biology,
Research Institute for Radiation Biology and Medicine,
Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima
734-8553, Japan.
Tel/Fax: +81-82-257-5808;
E-mail: kanaka55@hiroshima-u.ac.jp
and
Dae-Kee Kim, Graduate School of Pharmaceutical
Sciences, College of Pharmacy, Ewha Womans University,
11-1 Daehyun-dong, Seodaemun-gu, Seoul 120-750,
Korea.
Tel: +82-2-3277-3025; Fax: +82-2-3277-2467;
E-mail: dkkim@ewha.ac.kr
Funding Information
Yasuda Medical Foundation; Mochida Memorial Founda-
tion; Naito Foundation; Ministry of Education, Culture,
Sports, Science and Technology, Japan; Ministry of
Science, ICT and Future Planning through the National
Research Foundation, Korea; Ministry of Education,
Science and Technology, Korea
Received August 21, 2015; Revised November 11, 2015;
Accepted November 12, 2015
Cancer Sci 107 (2016) 140–148
doi: 10.1111/cas.12849
Recent strategies for treating CML patients have focused on investigating new
combinations of tyrosine kinase inhibitors (TKIs) as well as identifying novel
translational research agents that can eradicate CML leukemia-initiating cells
(CML-LICs). However, little is known about the therapeutic benefits such CML-LIC
targeting therapies might bring to CML patients. In this study, we investigated
the therapeutic potential of EW-7197, an orally bioavailable transforming growth
factor-b signaling inhibitor which has recently been approved as an Investiga-
tional New Drug (NIH, USA), to suppress CML-LICs in vivo. Compared to TKI treat-
ment alone, administration of TKI plus EW-7197 to CML-affected mice
significantly delayed disease relapse and prolonged survival. Notably, combined
treatment with EW-7197 plus TKI was effective in eliminating CML-LICs even if
they expressed the TKI-resistant T315I mutant BCR-ABL1 oncogene. Collectively,
these results indicate that EW-7197 may be a promising candidate for a new ther-
apeutic that can greatly benefit CML patients by working in combination with
TKIs to eradicate CML-LICs.
T he presence of the BCR-ABL1 fusion oncogene in HSCscauses the stem cell disease CML.(1,2) Although the dis-
covery of TKIs, such as the first-generation TKI IM and the
second-generation TKIs dasatinib, nilotinib, and bosutinib, has
dramatically improved the prognoses of CML patients, a cure
remains elusive. For example, in the Stop IM trial, 61% of
CML patients who achieved deep molecular response follow-
ing 2 years of IM treatment suffered relapses of their disease
after IM was stopped.(3) Many other studies have shown that
long-term treatment with IM or second-generation TKIs cannot
completely cure CML patients.(4–10)
CML-LICs are the cellular sources of the vast majority of
differentiated CML cells and are reportedly responsible for the
recurrence of CML disease following TKI therapy.(2,11,12)
Because TKIs target only actively dividing CML cells, quies-
cent CML-LICs escape TKI-mediated elimination. In addition,
it seems that some of the remaining quiescent CML stem cells
acquire TKI-resistant mutations, such as the T315I muta-
tion,(13) in the BCR-ABL1 and generate TKI-resistant CML-
LICs. Although it has been expected that the third-generation
version of the pan-Abl inhibitor AP24534 (ponatinib) would
improve the survival of TKI-resistant CML patients,(14) it
appears that CML-LICs can acquire additional BCR-ABL1
mutations that allow these cells to escape TKI-mediated kill-
ing.(13,15) Thus, many oncologists believe that, to completely
eradicate CML-LICs and prevent the recurrence of CML dis-
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ease, TKIs must be coupled with novel therapeutics targeting
alternative molecular pathways.(12)
It has been reported that TGF-b signaling plays both sup-
pressive and supportive roles in normal hematopoiesis and
leukemogenesis.(16) In particular, Yamazaki et al. found that
TGF-b signaling is required for the maintenance of HSCs
within their BM microenvironmental niche.(17) In the same
vein, we showed that intrinsic TGF-b signaling maintains
CML-LICs in vivo.(18) In contrast, Krause et al. showed that
supraphysiological levels of TGF-b1 secreted within the BM
niche can decrease numbers of CML-LICs.(19) Thus, from a
therapeutics point of view, both the promotion and suppression
of TGF-b signaling should be pursued for the development of
new agents able to eliminate CML-LICs.
EW-7197 is a novel kinase inhibitor that targets TGF-b type
I receptor kinase ALK5 and can be given to animals by oral
gavage.(20–22) We hypothesized that EW-7197 might be an
attractive candidate for a new CML therapeutic by virtue of its
ability to inhibit TGF-b signaling in vivo and thereby poten-
tially eliminate CML-LICs. In this study, we take the first
steps towards exploring whether EW-7197 might be of thera-
peutic benefit to CML patients by evaluating the effects of
combined treatment with EW-7197 and TKIs on CML-affected
mice in vivo.
Materials and Methods
Transduction ⁄ transplantation-based CML mouse models. Trans-
duction ⁄ transplantation-based CML mouse models used in this
study were established by infection of HSCs isolated from
C57BL ⁄6 mice (Sankyo-Lab Service, Tsukuba, Japan) with one
of three types of retroviruses carrying human BCR-ABL1 onco-
genes: MSCV-BCR-ABL1-ires-GFP; MSCV-BCR-ABL1; and
MSCV-BCR-ABL1-T315I mutant-ires-GFP. In all three cases,
retroviral packaging cells (Plat-E) were transiently transfected
with MSCV-BCR-ABL1 plasmids using FuGene6 (Roche, Man-
nheim, Germany).(18) HSCs transduced with retroviruses were
transplanted into irradiated (9 Gy) recipient C57BL ⁄6 mice as
described previously.(18)
Scl/Tal1-tTA x TRE-BCR-ABL1 double tg-CML mouse model. Scl/
Tal1-tTA (JAX strain 6209)(23) and TRE-BCR-ABL1 (JAX
strain 6202)(24) tg-mice (FVB ⁄N background) were purchased
from the Jackson Laboratory (Bay harbor, ME). These Scl/
Tal1-tTA and TRE-BCR-ABL1 animals were interbred to gener-
ate Scl/Tal1-tTA 9 TRE-BCR-ABL1 double tg-mice. These
mutants were maintained in cages supplied with drinking water
containing 20 lg ⁄mL Dox (Sigma, St Louis, MO). At 5 weeks
after birth, expression of the BCR-ABL1 oncogene was induced
by replacing the Dox-containing drinking water with normal
drinking water. Consistent with a previous report,(25,26) CML-
like disease developed in the double tg-mutants approximately
2–5 weeks after Dox withdrawal. All animal care in our labo-
ratory was in accordance with the guidelines for animal and
recombinant DNA experiments of Kanazawa University (Kana-
zawa, Japan).
Cell subset terminology. We consider the most primitive
murine “LT-CML stem cells” to be CD150+CD135CD48
cKit+LinSca1+ cells in tg-CML-affected mice, and murine
“CML-MPPs” to be KLS cells in transduction ⁄ transplantation-
based CML-affected mice and tg-CML-affected mice. We use
the term “CML-LICs” in the mouse context to refer collec-
tively to both of these subpopulations. In the human context,
we use “CML-LICs” to refer to CD34+CD38Lin cells from
CML patients.
Mouse survival. For “TKI-insensitive” survival experiments
using CML-affected mice, IM (Novartis, Basel, Switzerland)
was given to mice by oral gavage (200 mg ⁄ kg ⁄ day) on days
8–90 after transplantation of BCR-ABL1+ CML-MPPs.(18) For
“TKI-resistant” recurrence experiments using T315I CML-
affected mice, ponatinib (AP24534; Selleck Chemicals, Hous-
ton, TX) was given to mice by oral gavage (15 mg ⁄kg ⁄day)
on days 8–60 after transplantation of BCR-ABL1-T315I+
CML-MPPs. In both cases, we accessed a stock solution of
EW-7197(20) that was prepared at 2 lg ⁄mL in an artificial
gastric fluid solution (900 mL ddH2O containing 2.0 g NaCl,
7 mL conc. HCl, and 3.2 g pepsin). Once every 3 days
between days 15 to 90 post-transplantation with BCR-ABL1+
CML-MPPs, or between days 15 to 60 post-transplantation
with BCR-ABL1-T315I+ CML-MPPs, a dilution of this mix-
ture in artificial gastric fluid solution was given by oral gav-
age to CML-affected mice to achieve a final concentration of
2.5 mg EW-7197 ⁄kg body weight. Mouse survival was moni-
tored for 125 days in “TKI-insensitive” experiments and for
100 days in “TKI-resistant” recurrence experiments.
Isolation of murine CML-MPPs and LT-CML stem cells. For
experiments evaluating the effect of EW-7197 on CML-LICs
cocultured on OP-9 stromal cells in vitro, we isolated a CML-
MPP fraction containing retrovirus-infected GFP ⁄BCR-ABL1-
positive and GFP ⁄BCR-ABL1-T315I mutant-positive KLS
cells from CML-affected mice, as previously described.(18) For
experiments evaluating the expression levels of TGF-b target
genes in CML-LICs by quantitative real-time RT-PCR analy-
sis, we isolated CML KLS cells from tetracycline-inducible tg-
CML-affected mice (Data S1).
For experiments evaluating the PD of EW-7197 toward
primitive LT-CML stem cells in vivo, BM mononuclear cells
were isolated from the two hind limbs of tetracycline-inducible
tg-CML-affected mice at 5 weeks after Dox withdrawal, as
previously described.(25) We stained these cells with anti-Sca-1
(E13-161.7)-PE, anti-CD4(L3T4)-FITC, anti-CD8(53-6.7)-
FITC, anti-B220(RA3-6B2)-FITC, anti-TER119(Ly-76)-FITC,
anti-Gr-1(RB6-8C5)-FITC, and anti-Mac1(M1 ⁄70)-FITC (all
from BD Biosciences, Franklin Lakes, NJ), anti-CD48(HM48-
1)-APC-Cy7 and anti-CD150 ⁄SLAM(TC15-12F12.2)-Pacific
blue (both from BioLegend, San Diego, CA), and anti-cKit
(ACK2)-APC, and anti-CD135 ⁄Flk2 ⁄Flt3(A2F10)-biotin (both
from eBiosciences, San Diego, CA) antibodies, followed by
streptavidin-PE-Cy7 (BD Biosciences). We sorted these cells
by flow cytometry using a FACS Aria III instrument
(BD Biosciences) and isolated a cell fraction containing
CD150 ⁄SLAM-positive, CD135 ⁄Flk2 ⁄Flt3-negative, CD48-
negative KLS (CD150+CD135CD48KLS) cells, which were
deemed to be primitive LT-CML stem cells.(25)
Colony-forming capacity. To determine colony-forming
capacity after a combination treatment of EW-7197 plus IM,
or EW-7197 plus ponatinib, we cocultured freshly isolated
CML-LICs on OP-9 stromal cells in the presence of DMSO or
EW-7197 for 24 h.(18) Cells were then treated with additional
DMSO, 1 lM IM (LC Laboratories, Woburn, MA), or 1 lM
ponatinib (AP24534; Selleck Chemicals) and cultured for
another 2 days (total, 3 days). Colonies were counted 7 days
later as previously described.(18)
Pharmacokinetics. To assess the PK of EW-7197,
tetracycline-inducible tg-CML-affected mice were fasted over-
night and given EW-7197 (10 mg ⁄kg) by oral gavage as
described above. Blood samples were collected before treat-
ment and at 30 min, 2 h, 4 h, and 8 h post-treatment. Plasma
concentrations of EW-7197 were determined by liquid chro-
Cancer Sci | February 2016 | vol. 107 | no. 2 | 141 © 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Naka et al.
matography ⁄ tandem mass spectroscopy using an Agilent 1200
series HPLC and an Agilent 6410 triple quadrupole mass spec-
trometer equipped with an electrospray ionization source (Agi-
lent Technologies Santa Clara, CA).
Pharmacodynamics using Duolink in situ PLA technology. The
PD of EW-7197 was determined based on phosphorylation of
Smad3. EW-7197 (2.5 mg ⁄kg) was given to tetracycline-indu-
cible tg-CML-affected mice by oral gavage. Then we isolated
a cell fraction containing primitive LT-CML stem cells
(CD150+CD135CD48KLS cells) from tg-CML-affected
mice by flow cytometry using a FACSAria III instru-
ment (BD Biosciences).(27) Phospho-Smad3 was detected in
cells using anti-Smad3 (ab75512; Abcam, Cambridge, UK)
and rabbit anti-phospho-Ser423 ⁄425 Smad3 (ab51451;
Abcam) antibodies by the highly sensitive Duolink in situ
PLA technology approach.(27)
Determination of WBC numbers in PB. The CML-affected
mice received dasatinib (5 mg ⁄kg ⁄day) plus vehicle or EW-
7197 (2.5 mg ⁄kg every third day) by oral gavage for 30 days.
For blood cell counts, PB from the post-orbital vein was col-
lected in a heparinized microtube (Drummond Scientific, Broo-
mall, PA) and analyzed on a CellTac (Nihonkoden, Tokyo,
Japan).
Colony-forming capacity of primary human CML-LICs. Viable
BM mononuclear cells from three human patients with CP-
CML were purchased from Allcells (#06-255, #06-620, and
#147742, Alameda, CA). Cells were stained with anti-CD34
(8G12), anti-CD38(HIT2), anti-CD3(SK7), anti-CD16(3G8),
anti-CD19(SJ25C1), anti-CD20(L27), anti-CD14(M/P9), and
anti-CD56(NCAM16.2) antibodies (BD Biosciences). A mix-
ture of mAbs recognizing CD3, CD16, CD19, CD20, CD14,
and CD56 was used to identify Lin cells, and
CD34+CD38Lin cells were purified.(18) To determine the
effects of EW-7197 alone or a combination of EW-7197 plus
dasatinib, CD34+CD38Lin cells were cultured on OP-9 stro-
mal cells under hypoxic conditions (3% O2). After harvesting
and washing in PBS, the colony-forming ability of primitive
human CML-LICs was evaluated by culture in semi-solid
medium (Methocult GF+H4435; Stem Cell Technologies, Van-
couver, Canada).
Statistical analyses. Statistical differences were determined
using unpaired Student’s t-test for P-values, and the log–rank
non-parametric test for survival curves.
Results
Novel ALK5 kinase inhibitor EW-7197 suppresses growth of
CML-LICs in vitro. We first examined whether the novel ALK5
inhibitor EW-7197,(20) which inhibits intracellular TGF-b sig-
naling,(20,21) could suppress the colony-forming capacity of
freshly isolated murine CML-MPPs in vitro. Interestingly,
EW-7197 treatment dramatically reduced the colony-forming
capacity of CML-MPPs in vitro in a dose-dependent manner
(Fig. 1a). When EW-7197 treatment was combined with IM,
the in vitro colony-forming capacity of CML-MPPs was much
more efficiently suppressed than by treatment with IM alone
(Fig. 1b, columns 4–6 vs. 3).
To definitively show that EW-7197 can suppress the colony-
forming capacity of TKI-resistant CML-MPPs in vitro, we
further established a mouse model of TKI-resistant CML by
infecting HSCs with retrovirus expressing the TKI-resistant
T315I mutant BCR-ABL1 oncogene.(28) As expected, IM-treated
T315I+CML-MPPs fully retained their colony-forming capacity
(Fig. 1c, column 2). However, treatment of these T315I+CML-
MPPs with EW-7197 alone efficiently reduced their in vitro
colony-forming capacity despite their expression of the TKI-
resistant T315I mutant BCR-ABL1 oncogene (Fig. 1c, column
3). Although ponatinib alone had an inhibitory effect on the
in vitro colony-forming capacity of T315I+CML-MPPs, a
substantial subpopulation of these cells clearly survived the
treatment (Fig. 1d, column 2). Importantly, a combination of
EW-7197 plus ponatinib dramatically suppressed the in vitro
Fig. 1. EW-7197 inhibits the colony-forming
capacity of murine CML-LICs in vitro. (a,b) Colony-
forming capacity of freshly isolated GFP ⁄ BCR-ABL1+
cKit+LineageSca1+ (KLS) CML multipotent
progenitors (CML-MPPs) that were cocultured on
OP-9 stromal cells under hypoxic conditions (3% O2)
and treated for 3 days with either DMSO (control)
or the indicated concentrations of EW-7197 (a), or
for 3 days with DMSO or EW-7197, without or with
1 lM IM (b). Colony-forming capacity was
determined by culture in methylcellulose. Data
shown are the mean colony number  SD (n = 3).
(c,d) Colony-forming capacity of freshly isolated
T315I-BCR-ABL1-GFP+ KLS CML-MPPs that were
treated for 3 days with either DMSO (vehicle
control), 1 lM imatinib mesylate (IM), or 5 lM EW-
7197 (c), or for 3 days with DMSO or EW-7197, with
the addition (or not; DMSO) at 24 h post-EW-7197
treatment of 1 lM ponatinib for 48 h (d). Results
were analyzed as for (a,b). NS, not significant.
© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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colony-forming capacity of residual T315I+CML-MPPs (Fig. 1d,
column 3). Moreover, treatment in vitro with EW-7197 of CML-
MPPs isolated from tetracycline-inducible CML-affected mice
suppressed the endogenous mRNA expression of TGF-b tar-
get genes such as Smad7 and Cdkn1A (Fig. S1). These results
supported our hypothesis that EW-7197 might be a possible
candidate for a novel CML therapeutic capable of killing
CML-LICs.
Pharmacokinetics and PD of EW-7197 in tg-CML-affected mice.
We next determined the PK of EW-7197 in the bloodstream of
tetracycline-inducible tg-CML-affected mice by assessing its
plasma concentration–time profile post-treatment. We observed
that EW-7197 was rapidly absorbed into the bloodstream from
the gastrointestinal tract of tg-CML-affected mice, and was
then eliminated with a terminal phase half-life (T1/2) of
3.26  2.47 h (Fig. 2a). The maximum concentration (Cmax)
of the drug in plasma was determined to be 625.0  529.7 ng
⁄mL (n = 7) at 30 min post-administration.
The PD of EW-7197 were established by examining phos-
phorylation levels of Smad3, which is a direct target of TGF-b
type I receptor kinase ALK5 in the intracellular TGF-b signal-
ing pathway. To this end, we used the highly sensitive
Duolink in situ PLA technology approach using rabbit anti-
bodies specific for phospho-Ser423 ⁄425 Smad3 and mouse
anti-Smad3 antibody. This assay system is highly sensitive and
detects miniscule amounts of a specific protein in fixed cells
using an amplified fluorescent signal. As a positive control, we
treated primitive LT-CML stem cells in vitro with TGF-b1 for
(a) (b)
(c)
Fig. 2. Pharmacokinetics and pharmacodynamics of EW-7197 in tetracycline-inducible transgenic (tg)-CML-affected mice. (a) Concentration–time
profile of EW-7197 in tetracycline-inducible tg-CML-affected mice. EW-7197 (10 mg ⁄ kg body weight) was given orally to Scl/Tal1-tTA 9 TRE-BCR-
ABL1 double tg mice at 5 weeks after doxycycline withdrawal. Blood samples were obtained from tg-CML-affected mice pre- and post-adminis-
tration of EW-7197, and plasma concentrations of the drug were determined by liquid chromatography ⁄ tandem mass spectroscopy. Data are the
mean concentration of EW-7197  SD (n = 7). (b,c) Analyses of suppression of Smad3 phosphorylation by EW-7197 in long-term (LT)-CML stem
cells in vivo. (b) Duolink in situ proximity ligation assay analysis. Tg-CML-affected mice received oral EW-7197 (2.5 mg ⁄ kg). At the indicated
time points after treatment, mice were killed and LT-CML stem cells (CD150+CD135CD48KLS) were isolated from hind limbs. Levels of phos-
pho-Smad3 (red) in LT-CML stem cells were assessed by Duolink in situ proximity ligation assay technology. Nuclei were visualized by DAPI
(blue). Images shown are representative of three animals examined per time point. Scale bar = 10 lm. (c) Quantitation of the “dot number” of
phospho-Smad3 foci per single LT-CML stem cell in the panels in (b) at the indicated times after treatment with EW-7197. Values were deter-
mined using the Duolink Image J software tool. Horizontal bars, cumulative mean values of three independent experiments. *P < 0.00005 ver-
sus 0 h. NS, not significant.
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30 min and detected obvious fluorescent foci of phospho-
Smad3 using Duolink in situ PLA (data not shown). To
determine the effect of EW-7197 on Smad3 phosphorylation,
we gave 2.5 mg ⁄kg EW-7197 to tg-CML-affected mice, iso-
lated LT-CML stem cells from these animals at various time
points up to 120 h after treatment, and immediately evaluated
levels of Smad3-Ser423 ⁄425 phosphorylation in these cells.
We observed a decrease in numbers of fluorescent foci that
began at 6 h after treatment and continued until 48 h after
treatment with EW-7197 (Fig. 2b,c), indicating that EW-7197
effectively inhibits Smad3 phosphorylation in vivo. These data
show that in vivo administration of EW-7197 efficiently
decreases ALK5 kinase activity in primitive LT-CML stem
cells of tg-CML-affected mice. Furthermore, this suppression
is maintained for at least 48 h after treatment.
Prolonged survival of CML-affected mice treated with a combi-
nation of TKI plus EW-7197. Our observation that EW-7197
decreased the colony-forming capacity of CML-MPPs in vitro
prompted us to examine whether this orally bioavailable TGF-
b signaling inhibitor was of any therapeutic benefit to CML-
affected mice. Accordingly, we first evaluated the overall sur-
vival of CML-affected mice that were treated with IM, or with
EW-7197 alone or in combination with IM. Although treat-
ment with IM alone (200 mg ⁄kg daily) delayed disease onset
compared to the vehicle-treated group, IM-treated CML-
affected mice experienced recurrence of BCR-ABL1+ disease
well before the end of the 125-day observation period (Fig. 3a,
group 3 vs. 1). Treatment once every 3 days with EW-7197
alone did not markedly extend the survival of CML-affected
mice beyond that of IM-treated CML mice (Fig. 3a, group 2
Fig. 3. Combined treatment with tyrosine kinase inhibitor plus EW-7197 prolongs the survival of CML-affected mice. (a) Irradiated C57BL ⁄ 6
recipient mice were transplanted with HSCs transduced with the BCR-ABL1 oncogene. At 8 days post-transplantation, recipient mice received
either vehicle or imatinib mesylate (IM; 200 mg ⁄ kg ⁄ day). At 15 days post-transplantation, these CML-affected mice received additional vehicle
alone (1), vehicle plus EW-7197 (2.5 mg ⁄ kg every third day) (2), IM plus vehicle (3), or IM plus EW-7197 (4). Mouse survival was monitored for up
to 125 days. Results shown are cumulative data obtained from four independent experiments. (b,c) EW-7197 (EW) treatment reduces the fre-
quency of CML multipotent progenitors in vivo. (b) CML-affected mice received dasatinib (5 mg ⁄ kg ⁄ day) plus vehicle or EW-7197 (2.5 mg ⁄ kg
every third day) by oral gavage for 30 days after bone marrow transplantation. Data shown are representative flow cytometric analyses high-
lighting GFP ⁄ BCR-ABL1+ cKit+LineageSca1+ (KLS) cells (red rectangles). Cells were gated on GFP+, Lineage. (c) Mean frequency  SD of GFP
⁄ BCR-ABL1+ KLS cells among total GFP ⁄ BCR-ABL1+ CML cells (n = 3) from the CML-affected mice in (b).
© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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vs. 1). However, the combined treatment of IM plus EW-7197
significantly prolonged the survival of CML-affected mice
(Fig. 3a, group 4 vs. 3). Thus, these results indicated that EW-
7197 possesses therapeutic benefits in combination with a TKI
in a CML-affected mouse model.
Eradication of murine CML-MPPs in vivo by a combination of
TKI plus EW-7197. To further evaluate the benefits and risks of
EW-7197 treatment, we examined the effects of this agent on
fully differentiated and mature BCR-ABL1-GFP+ CML cells
in vivo. Surprisingly, treatment of CML-affected mice with
EW-7197 alone appeared to increase WBC numbers in PB and
to promote splenomegaly (Fig. S2, left). These data implied
that EW-7197 commits CML-LICs to differentiate into mature
CML cells and promotes their proliferation, and thus could
pose a significant risk to patients if used as a single treatment.
Strikingly, however, combined treatment of CML-affected
mice with the TKI dasatinib plus EW-7197 completely blocked
both the WBC elevation in PB and splenomegaly associated
with EW-7197 monotherapy (Fig. S2, right). Thus, in vivo,
treatment with a TKI can overcome the unfavorable prolifera-
tion of differentiated CML cells induced by EW-7197.
We next determined the effect of EW-7197 on primitive
CML-KLS cells in CML-affected mice in vivo. In contrast to
its effects on the differentiation and proliferation of mature
CML cells, the frequency of CML-KLS cells among BCR-
ABL1-GFP+CML cells isolated from BM of CML-affected
mice was dramatically decreased by EW-7197 treatment
(Fig. 3b,c). Significantly, although dasatinib alone also reduced
the frequency of CML-KLS cells, the combined treatment of
dasatinib plus EW-7197 had a much greater repressive effect
on this population (Fig. 3b,c). These data show that EW-7197
can inhibit the self-renewal capacity of CML-MPPs in CML-
affected mice. Collectively, our results suggest that combined
treatment with EW-7197 and TKI dasatinib may bring signifi-
Fig. 4. Combined treatment with ponatinib and EW-7197 (EW) reduces disease relapse rate in mice with tyrosine kinase inhibitor (TKI)-resistant
BCR-ABL1-T315I+ CML. (a) Prolonged survival of TKI-resistant T315I CML-affected mice receiving ponatinib plus EW-7197. Irradiated C57BL ⁄ 6
recipient mice were transplanted with HSCs transduced with the BCR-ABL1-T315I mutant oncogene. At 8 days post-transplantation, recipient
mice received either vehicle or ponatinib (15 mg ⁄ kg ⁄ day). At 15 days post-transplantation, these TKI-resistant T315I CML-affected mice received
additional vehicle alone (1), vehicle plus EW-7197 (2.5 mg ⁄ kg every third day) (2), vehicle plus ponatinib (15 mg ⁄ kg ⁄ day) (3), or ponatinib plus
EW-7197 (4) for 60 days post-transplantation. Mouse survival and disease recurrence were monitored for up to 100 days. Results shown are
cumulative data obtained from four independent experiments. (b) Reduced frequency of TKI-resistant CML multipotent progenitors following
treatment with ponatinib plus EW-7197 in vivo. TKI-resistant T315I CML-affected mice received ponatinib (15 mg ⁄ kg ⁄ day) plus vehicle or EW-
7197 (2.5 mg ⁄ kg every third day) by oral gavage for 30 days. Data shown are representative flow cytometric analyses highlighting T315I BCR-
ABL1-GFP+ cKit+LineageSca1+ (KLS) cells (red rectangles). Cells were gated on GFP+, Lineage. (c) Mean frequency  SD of BCR-ABL1-T315I-GFP+
KLS cells among total BCR-ABL1-T315I-GFP+ CML cells (n = 3) from the T315I CML-affected mice in (b).
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cant therapeutic benefits to CML patients by eradicating CML-
MPPs.
Suppression of disease recurrence in TKI-resistant CML-affected
mice by treatment with EW-7197 plus ponatinib. A serious prob-
lem for human CML patients is the generation during or post-
TKI therapy of CML-LICs bearing a BCR-ABL1 oncogene
with a TKI-resistant mutation (such as T315I).(13) Given that
EW-7197 treatment suppressed the colony-forming capacity of
murine TKI-resistant T315I+CML-MPPs in vitro (as in Fig. 1c,
d), we wondered whether this TGF-b signaling inhibitor might
block CML-MPP function even after the acquisition of TKI
resistance. To answer this question, we evaluated the overall
survival of TKI-resistant CML-affected mice with BCR-ABL1-
T315I+ disease that were treated with ponatinib alone (15 mg
⁄kg daily), EW-7197 alone (2.5 mg ⁄kg every third day), or
both in combination. Although treatment with ponatinib alone
markedly delayed CML onset compared to vehicle-treated con-
trols, CML recurred in ponatinib-treated CML-affected mice
after discontinuation of treatment (Fig. 4a, group 3 vs. 1).
Treatment with EW-7197 alone once every 3 days did not pro-
long the survival of T315I CML-affected mice compared to
the vehicle-treated group (Fig. 4a, group 2 vs. 1). Neither was
there an obvious decrease at 60 days post-transplantation in
the efficiency of induction of TKI-resistant CML disease in
mice that received BCR-ABL1-T315I+CML-MPPs and were
treated with ponatinib plus EW-7197 compared to treatment
with ponatinib alone. However, the rate of recurrence of TKI-
resistant CML in mice receiving ponatinib plus EW-7197 was
dramatically decreased after discontinuation of treatment com-
pared to the rate in the group treated with ponatinib alone
(Fig. 4a, group 4 vs. 3). These results indicate that oral co-
administration of EW-7197 and ponatinib can reduce the dis-
ease-relapsing capacity of T315I+CML-MPPs in vivo.
To evaluate the in vivo effects of EW-7197 on TKI-resistant
CML-MPPs in T315I CML-affected mice, we focused on self-
renewal capacity. Consistent with our observations in Fig-
ure 3(b,c), EW-7197 treatment effectively blocked the self-
renewal of T315I+CML-KLS cells (Fig. 4b,c). Combined treat-
ment with ponatinib and EW-7197 led to even greater suppres-
sion of T315I CML-KLS cells (Fig. 4b,c). Thus, EW-7197 can
efficiently block the self-renewal of even TKI-resistant CML-
MPPs in vivo.
EW-7197 suppresses in vitro colony-forming capacity of human
CML-LICs. To assess the relevance of our mouse results to the
human situation, we examined whether EW-7197 could sup-
press the in vitro colony-forming capacity of primary human
CML-LICs obtained from CP-CML patients. We used cell-
sorting to isolate the CD34+CD38Lin cell population, which
includes CML-LICs, from three CP-CML patients and cocul-
tured these cells on OP-9 stromal cells under hypoxic (3% O2)
conditions.(18) Intriguingly, EW-7197 significantly suppressed
the in vitro colony-forming capacity of all three samples of
human CML-LICs (Fig. 5). When EW-7197 treatment was
combined with dasatinib, the in vitro colony-forming capacity
Fig. 5. EW-7197 inhibits the colony-forming
capacity of human CML leukemia-initiating cells
in vitro. Colony-forming capacity of
CD34+CD38Lin cells isolated from bone marrow
mononuclear cells obtained from three CP-CML
patients. CML leukemia-initiating cells were
cocultured on OP-9 stromal cells under hypoxic
conditions (3% O2) and treated for 3 days with
either DMSO (vehicle control) or 5 lM EW-7197 (a,
b, and c, left panel), or for 3 days with DMSO or
EW-7197, with the addition (or not; DMSO) at 24 h
post-EW-7197 treatment of 500 nM dasatinib for
48 h (c, right). Colony-forming capacity was
determined by culture in methylcellulose. Data
shown are the mean colony number  SD (n = 3).
© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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of the human CML-LICs was much more efficiently sup-
pressed than by treatment with dasatinib alone (Fig. 5c). These
data suggest that treatment with a combination of TKIs and
EW-7197 may be a promising strategy for eradicating primi-
tive CML-LICs in human CML patients.
Discussion
Because the intrinsic TGF-b signaling pathway plays an essen-
tial role in the maintenance of immature CML-LICs
in vivo,(18) the inclusion of a TGF-b inhibitor in the treatment
of CML patients could be a promising therapeutic approach. In
this study, we showed that the novel orally bioavailable TGF-
b inhibitor EW-7197 can suppress murine CML-LICs in vivo
and human CML-LICs in vitro. Notably, this strategy, which
is based on inhibiting intrinsic TGF-b signaling, also
suppressed recurrence in mice of disease associated with the
TKI-resistant BCR-ABL1 T315I mutation, the same alteration
responsible for disease recurrence in CML patients. Our results
therefore suggest that EW-7197 may be an attractive candidate
for a new therapy able to eradicate CML-LICs in CP-CML
patients when used in combination with TKIs.
It has recently been reported that CML-LICs cells are not
oncogene-addicted, and that a therapeutic strategy that targets
only ABL1 kinase activity cannot completely eliminate CML-
LICs.(29–31) Thus, it is important to develop novel therapeutics
that do not depend on inhibiting BCR-ABL1 kinase activ-
ity.(12) In this study, EW-7197 inhibited ALK5 and thus
efficiently blocked intrinsic TGF-b signal transduction in
CML-LICs in vitro and in vivo even after they had developed
TKI resistance. These results suggest that TGF-b signaling is
an alternative molecular pathway that does not depend on
BCR-ABL1 activity to maintain CML-LICs in vivo, and that
combined treatment with EW-7197 and TKIs may therefore be
able to eradicate “TKI-insensitive” and “TKI-resistant” CML-
LICs in human CML patients.
Interestingly, Krause et al. have reported that CML-affected
mice transgenically overexpressing the receptor for parathyroid
hormone on osteoblastic cells undergo increased bone remodel-
ing associated with elevated TGF-b1 expression and show pro-
longed overall survival.(19) In contrast, the results of our study
indicate that inhibition of intrinsic TGF-b signaling may in
fact “wake up” CML-LICs so that they can become activated
and thus vulnerable to killing by TKIs.(18,32) These opposing
results are likely due to the well-established differences in the
effects of differing doses of TGF-b1 on hematopoietic cells.(16)
Our work clearly revealed that inhibition of intrinsic TGF-b
signaling in CML-LICs is a promising strategy for suppressing
their function. We therefore believe that the intrinsic TGF-b
signaling pathway should be considered for the development
of novel CML therapeutics.
In conclusion, we have shown that the novel orally bioavail-
able TGF-b signaling inhibitor EW-7197 can suppress the
function of CML-LICs in vitro and in vivo. EW-7197 has
already been approved by the FDA and certified as an Investi-
gational New Drug. A phase I clinical trial for the use of EW-
7197 in the treatment of patients with advanced solid tumors
has been initiated (NCT02160106, NIH). Our continuing inves-
tigation of EW-7197 should contribute to the development of
new therapeutics that can specifically suppress the effects of
TGF-b signaling on CML-LICs, and so may provide concrete
clinical benefits to CP-CML patients.
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Abbreviations
BM bone marrow
CP chronic phase
Dox doxycycline
EW-7197 [N-((4-([1,2,4]-triazolo[1,5-a]pyridin-6-yl)-5-(6-methyl
pyridin-2-yl)-1H-imidazol-2-yl) methyl)-2-fluoroaniline]
HSC hematopoietic stem cell
IM imatinib mesylate
KLS cKit+LineageSca1+
LIC leukemia-initiating cell
Lin Lineage
LT long-term
MPP multipotent progenitors
MSCV murine stem cell virus
PB peripheral blood
PD pharmacodynamics
PE phycoerythrin
PK pharmacokinetics
PLA proximity ligation assay
Tg transgenic
TGF-b transforming growth factor-b
TKI tyrosine kinase inhibitor
WBC white blood cell
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